Gene-Addition/Editing Therapy in Sickle Cell Disease
Presse Med. 2023 Nov 22:104214. doi: 10.1016/j.lpm.2023.104214. Online ahead of print.ABSTRACTGene therapy is an innovative strategy that offers potential cure for patients with sickle cell disease, and no appropriate donor for transplant consideration. While we await long term data from these clinical trials, we remain optimistic that gene therapy will become a standard of care for curative treatment in sickle cell disease. As gene therapy becomes a standard of treatment in sickle cell disease, we must also acknowledge the potential for financial burden to patients. We also must acknowledge the prevalence of sickle cell disease in low-resource settings. Hopefully, as we learn more about gene therapy, we can assess ways to overcome the financial toxicity that comes with this therapy.PMID:38000628 | DOI:10.1016/j.lpm.2023.104214
Source: Presse Medicale - Category: General Medicine Authors: Galia Pollock Olivier Negre Jean-Antoine Ribeil Source Type: research
More News: Clinical Trials | Gene Therapy | General Medicine | Genetics | Learning | Sickle Cell Anemia | Toxicology | Transplants | Universities & Medical Training